0001193125-26-219481
SEC filingKura Oncology reported $18.3M in revenue for Q1 FY2026, up 29.5% year-over-year, while operating losses widened to -$78.8M amid continued investment in clinical development and the early commercial phase of KOMZIFTI — a transition marked by zero-cost inventory driving high gross margins but not yet offsetting R&D scale.
Revenue for Q1 FY2026 totaled $18.3M, an increase of 29.5% compared to $14.1M in Q1 FY2025. This growth reflects the first full quarter of commercial activity for KOMZIFTI, which received FDA approval in November 2025. As noted in Management’s Discussion, prior to approval, manufacturing costs for KOMZIFTI were recorded as research and development expenses — resulting in zero-cost inventory. This accounting treatment directly supports the observed gross margin of 98.6%, as initial product sales incurred minimal cost of goods sold.
Operating income declined to -$78.8M from -$64.7M in the prior-year period, a 21.8% deterioration. The increase in personnel costs and other expenses was primarily due to higher headcount costs supporting ongoing clinical trials. Darlifarnib-related R&D expenses also rose, driven by increased costs associated with our Phase 1 clinical trial. These investments reflect strategic prioritization of pipeline advancement alongside commercial execution — a dynamic consistent with the company’s stated objective to advance multiple late-stage programs.